Welcome to our dedicated page for Virpax Pharmaceuticals news (Ticker: VRPX), a resource for investors and traders seeking the latest updates and insights on Virpax Pharmaceuticals stock.
Virpax Pharmaceuticals (VRPX) is advancing non-opioid pain management through innovative drug delivery systems, including metered-dose sprays and liposomal formulations. This news hub provides investors and industry observers with timely updates on preclinical developments, regulatory milestones, and strategic partnerships.
Our curated collection of VRPX news offers essential insights into the company's progress in developing alternatives to traditional pain therapies. Track updates across key areas including product pipeline advancements, intellectual property developments, and global research collaborations that shape the future of pain treatment.
Discover official press releases detailing Virpax's work on enkephalin-based therapies and hydrogel encapsulation technologies. Stay informed about critical updates through verified financial disclosures and scientific progress reports, all maintained in one centralized location for efficient research.
Bookmark this page for ongoing access to VRPX's latest achievements in pharmaceutical innovation. Check regularly for new developments in their mission to enhance therapeutic outcomes while reducing opioid dependency risks.
Virpax Pharmaceuticals (NASDAQ: VRPX) announced significant progress in its Envelta development program, a non-opioid pain product candidate. Recently completed dose ranging studies in rats and dogs showed Envelta was well-tolerated with no adverse effects. The data will support the IND application to the FDA and establish safe dosing for first-in-human trials, expected to file by Q2 2024. The program is funded by an in-kind grant from the National Center for Advancing Translational Sciences (NCATS) under the NIH.
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) has announced the appointment of
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) announced its 2022 financial results, revealing a significant increase in operating expenses due to legal costs and R&D investments. General and administrative expenses surged by 54% to $11.1 million, while R&D expenses rose by 122% to $10.8 million. The company is advancing its drug candidates, including Probudur, targeting postoperative pain with new formulations. Additionally, collaborations with leading physicians and upcoming IND submissions for Envelta and NobrXiol are underway. As of December 31, 2022, Virpax had approximately $19 million in cash and is pursuing non-dilutive funding strategies.
Virpax Pharmaceuticals (NASDAQ: VRPX) has completed FDA-required preclinical toxicology studies for its Molecular Envelope Technology (MET), which enhances drug delivery for its pain management and epilepsy product candidates. This study aims to evaluate the safety of MET in preparation for IND submissions. Developed by Nanomerics Ltd., this technology is crucial for multiple drug candidates including AnQlar™ and Envelta™. Dr. Jeffrey Murray, a former FDA expert, is advising the company on clinical trial design, emphasizing MET's potential to improve drug administration while reducing interactions and dosage needs.
Virpax Pharmaceuticals (NASDAQ: VRPX) has engaged New England Investors, LLC as its out-licensing advisor for Envelta in China, aimed at managing acute and chronic pain. Envelta, a patent-pending intranasal product, utilizes Molecular Envelope Technology to cross the blood-brain barrier, reducing side effects associated with traditional pain medications. Funded by an NCATS grant, Envelta is an innovative non-opioid alternative targeting various pain conditions. The company believes this partnership will significantly enhance its licensing efforts in China, leveraging New England Investors' expertise in cross-border transactions.
Virpax Pharmaceuticals (NASDAQ: VRPX) has announced the collaboration with pain expert Dr. Neil K. Singla to aid in the clinical development strategy for its product candidate, Probudur. This ultra-long-acting anesthetic aims to reduce opioid dependence post-surgery, with animal studies showing pain control for up to 96 hours. Virpax has partnered with the U.S. Army Institute of Surgical Research for further evaluations. The company anticipates moving forward with Investigational New Drug applications and initiating human clinical trials soon. The focus is on non-addictive pain management solutions and addressing significant market needs.
Virpax Pharmaceuticals (NASDAQ: VRPX) has appointed Destum Partners as its exclusive advisor for global partnering and licensing efforts, focusing on two OTC products: Epoladerm for osteoarthritis pain and AnQlar as a viral barrier. Destum will also assist in finding a partner for Probudur, an Rx product for postoperative pain management. CEO Anthony Mack emphasized the need for specialized transactional experience to maximize shareholder value. Destum aims to develop opportunities around Virpax's innovative drug-delivery systems targeting pain and CNS disorders.
Virpax Pharmaceuticals (NASDAQ: VRPX) announced the engagement of Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to advance the development of NobrXiol, a cannabidiol product aimed at managing epilepsy. Their expertise includes advising on trial design and regulatory pathways. NobrXiol employs Nanomerics' Molecular Envelope Technology for nasal delivery to enhance efficacy in reaching the brain. This partnership is expected to bolster patient recruitment and advocacy efforts.
Virpax Pharmaceuticals (NASDAQ: VRPX) has received guidance from the FDA on the pre-Investigational New Drug (PIND) application for its cannabidiol product candidate, NobrXiol, aimed at managing epilepsy in children and adults. Utilizing the Nanomerics Molecular Envelope Technology, NobrXiol aims to deliver cannabidiol directly to the brain through the nasal route. The FDA's feedback paves the way for IND-enabling studies, helping Virpax move forward with regulatory planning and potential clinical trials.
Virpax Pharmaceuticals (NASDAQ:VRPX) reported financial results for Q3 2022, highlighting operating expenses of $4.9 million in general and administrative costs and $2.8 million in R&D expenses, up from $1.7 million year-over-year. The company experienced an operating loss of approximately $7.7 million, compared to $3.2 million in Q3 2021. Cash used in operations totaled $16.3 million for the nine months ended September 30, 2022. Virpax is focusing on progressing its product pipeline, including plans for clinical trials in 2023 and potential licensing opportunities.
